In the spirit of breaking convention and uncovering the bigger story, Roche organises events to bring people together to explore this narrative... welcome to Future-proofing Healthcare. Neuroscience is an area that juxtaposes the mystery and intrigue of the human brain’s functionality with the ongoing battle to effectively manage and treat neurological diseases. One of the cruellest traits of neurodegenerative diseases is that they can take away from a person the sense of who they are and their ability to make sense of the world around them.
As part of the Future-proofing Healthcare series the NeuroSense event explores the way the brain uses the five senses to understand the world. It addresses the link between stimulation of the senses and development of the brain, what happens when the brain is damaged and what the future looks like for healing the brain and managing neurological conditions.
“Science is a huge puzzle and neuroscience is the biggest puzzle of all. It takes people from all disciplines to give us answers”
Professor Annette Dolphin, President Elect of the British Neuroscience Association
"Recognising the unmet need in chronic neurological diseases, a strategic decision was made to invest more heavily in neuroscience and we want to do it in a more innovative way”
Dr Marius Scholtz, Neuroscience Lead Roche Products Limited
Select from the below to watch NeuroSense talks from academics, patients, healthcare professionals, researchers and technology developers from across the neuroscience community.
Dr Hannah Critchlow is a neuroscientist with a grounding in neuropsychiatry. Hannah demystifies the human brain for radio, TV and live audiences, producing and presenting neuroscience oriented interactive experiences for the general public. She has appeared on Sky, BBC and ITV channels, and has presented live events to more than 30,000 people globally.
In 2017 Hannah was appointed Outreach Fellow for Magdalene College, Cambridge. In 2014, the Science Council named Hannah as a Top 100 UK Scientist for her work in science communication. She has also been named as one of Cambridge University’s Inspirational and Successful Women in Science, and was awarded a Cambridge University Fellowship during her PhD.
More recently, Hannah appeared on Channel 4’s 2016 show Your Face Says It All, in which cutting-edge science reveals the secrets of the human face.
Professor Francis McGlone is Professor in Neuroscience at Liverpool John Moores University where he is Head of the Somatosensory and Affective Neuroscience Group, he is also President of the International Association for the Study of Affective Touch and Director of Neuro-Consulting business, NeuroSci.
Professor McGlone takes a multidisciplinary approach to the human brain and mind and is currently studying c-fibres (pain, itch and pleasure nerves). His previous research has studied whether lack of c-fibre stimulation has a role in the development of neurological conditions, such as dementia and autism.
Emma Lawton was diagnosed with early onset Parkinson’s at the age of 29. Since then, she has made it her mission to raise awareness of the condition and continue her life as she planned. Emma campaigns and shares her story on social media, has published her own book on dealing with Parkinson’s and featured in a BBC documentary about assistive technology while continuing her career as a Creative Director.
In 2015 Emma won the CharityComms Inspiring Communicator award for her fundraising for Parkinson’s and in 2017 she was listed as one of Management Today’s 35 women under 35. She has written articles for the Telegraph and Cosmopolitan and is a 3-time TEDx speaker. Fascinated by technology and its importance in managing health conditions, Emma is also Devices and Apps Strategist at Parkinson’s UK.
Professor Steven Gill is a Professor of Neurosurgery, a consultant neurosurgeon and pioneer of the Convection Enhanced Delivery (CED) system which addresses the challenge of getting treatments past the blood brain barrier and into the brain.
Specialist robots insert micro-catheters directly into the brain with extreme precision. This technology has the potential to treat a wide range of neurological disorders and is currently being used to treat patients with malignant brain tumours and Parkinson’s disease.
Professor Annette Dolphin is Professor of Pharmacology in the Department of Neuroscience, Physiology and Pharmacology at UCL and President Elect of the British Neuroscience Association.
Following periods studying at the University of Oxford, the Institute of Psychiatry, Paris, Yale and the National Institute for Medical Research, Professor Dolphin is currently researching the function of neuronal voltage-gated calcium channels, and the mechanism of action of drugs that target these channels.
The British Neuroscience Association is the largest UK organisation representing and promoting neuroscience and neuroscientists and covers the whole range of neuroscience, from ion channels to whole animal behaviour to real-life applications in the clinic and beyond.
Date of preparation: June 2018